LSE · AZN.L
AstraZeneca PLC
£130.52+£2.88 (+2.26%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 17.04% below the high.
Loading market information…
LSE · OPT.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 04:22 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Optima Health plc’s quoted price sits in the upper half of its reported 52-week range, 7.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Optima Health plc’s next earnings report is currently expected on Dec 16, 2026, with estimated earnings per share of £0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Optima Health plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Optima Health Plc specializes in delivering workplace health and employee wellbeing solutions. Their extensive range of offerings includes initiatives for engagement and overall wellness, alongside dedicated services for mental health and musculoskeletal care. Established in 1947, the company's main office is situated in Sheffield, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 |
|---|
| Dec 11, 2024 |
| £0.01 |
| £50.80M+0.1% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£130.52+£2.88 (+2.26%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 17.04% below the high.
£18.14-£0.18 (-0.96%)
GSK plc’s quoted price sits in the lower half of its reported 52-week range, 20.51% below the high.
£3.18-£0.56 (-15.05%)
Haleon plc’s quoted price sits in the lower half of its reported 52-week range, 26.73% below the high.
$37.52+$0.41 (+1.1%)
Roivant Sciences Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.72% below the high.
£11.21+£0.02 (+0.13%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 21.42% below the high.
£2.04£0.00 (0.0%)
Diaceutics PLC’s quoted price sits in the upper half of its reported 52-week range, 3.1% below the high.
£1.90£0.00 (0.0%)
Kooth plc’s quoted price sits in the upper half of its reported 52-week range, 6.65% below the high.
£0.05+£0.00 (+1.02%)
MedPal AI Plc’s quoted price sits in the lower half of its reported 52-week range, 41.76% below the high.
